Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Group-B type-III Coxsackie virus gene vaccine

A coxsackie virus and gene vaccine technology, applied in gene therapy, antiviral agents, virus antigen components, etc., can solve problems such as poor safety and poor immunogenicity

Inactive Publication Date: 2006-05-17
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to provide a kind of Coxsackie virus group B type 3 genetic vaccine for the deficiency of poor immunogenicity and poor safety in the existing CVB vaccine, that is, a genetic vaccine for preventing and treating Coxsackie virus group B type 3 myocarditis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group-B type-III Coxsackie virus gene vaccine
  • Group-B type-III Coxsackie virus gene vaccine
  • Group-B type-III Coxsackie virus gene vaccine

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0005] Embodiment 1: The CVB3 gene vaccine of this embodiment is a pCEP4-CVB3VP1 plasmid composed of the VP1 gene of CVB3 encoding the main neutralizing antigen and the plasmid pCEP4 as a eukaryotic expression vector. For the gene sequence of pCEP4-CVB3VP1, see the gene sequence below list.

specific Embodiment approach 2

[0006] Specific implementation mode 2: This implementation mode introduces the genetic vaccine of the present invention in detail.

[0007] 1. The materials used are:

[0008] 1. Virus: The CVB3 virus strain is a standard strain in my country, donated by Professor Zhong Xuekuan from the Keshan Disease Research Institute of the China Endemic Disease Center. The virus was passaged in Vero cells, and the TCID50 was 10-8.

[0009] 2. Vectors and bacterial strains: The vectors used in the experiment include pCR2.1 and pCEP4, both of which are products of Invitrogen Corporation of the United States. The size of pCR2.1 is 3.9kb. It is a TA cloning vector, which is especially suitable for PCR product cloning. The vector contains Ptac promoter and LacZα gene, and the multiple cloning site is in the middle of the gene, so the recombinant can be preliminarily screened by blue-white selection . In addition, pCR2.1 has M13 forward primer and M13 reverse primer at both ends of the multip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The group-B type-III coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing CVB3 virus gene vaccine as one kind of pcCVP4-CVB1VP1 plasmid comprising VP1 gene with CVB3 coding main neutral antigen and plasmid pCEP4 as eukaryotic expression vector. Compared with traditional vaccines, the gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.

Description

technical field [0001] The present invention relates to a vaccine for preventing Coxsackie virus infection. Background technique [0002] Vaccines traditionally used to prevent Coxsackie virus (CVB) infection include inactivated vaccines and live attenuated vaccines. During the inactivation process of inactivated vaccines, the antigenicity is weakened and important epitopes are lost, so that the body cannot produce sufficient protective immunity. Live attenuated vaccines often cause immunosuppression after inoculation. Insufficient attenuation can lead to clinical virus infection, and live virus vaccines may reverse mutations to produce pathogenic phenotypes, while over-attenuation will reduce the vaccine potency and weaken its efficacy. The ability to stimulate the body's immunity. New CVB vaccines include subunit vaccines and synthetic peptide vaccines. Subunit vaccines are safe, non-toxic, and have few side effects, but poor immunogenicity. In recent years, vaccines i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K39/12A61P31/12
Inventor 田野钟照华王言肖建敏孟繁超
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com